About Us
Our Science
Newsroom
- Press Releases
- Events & Presentations
Investor Relations
Contact

Financial Information

Overview
Corporate Governance
Financial Information
Annual Reports & Proxy Statements
Investor Contact Information

SEC and XBRL Filings »

Quick Links

Home
About Us
Our Science
Newsroom
Investor Relations
Contact

Contact

ir@panbela.com

Sign up to receive press releases via email:

Leave this field empty if you're human:

News & Events

Panbela Announces Pricing of Approximately $15 Million Public Offering

Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101)

Panbela Announces 1-for-40 Reverse Stock Split effective 1/13/23

Copyright ©2023 Panbela Therapeutics, Inc. All Rights Reserved.